Table 1.
Small-molecule inhibitors in clinical trials for glioblastoma and other cancers.
| S.NO | Name of the Drug | Drug Target | Clinical Trial | Indication |
|---|---|---|---|---|
| 1 | Ventictumab | FZD1, 2, and 5 | Phase I | Solid tumors, breast, and pancreatic |
| 2 | Ipafrecept | FZD8 | Phase I | Pancreatic, hepatocellular, ovarian |
| 3 | Cirmtuzumab | Phase II | Breast, lymphoma cancer | |
| 4 | WNT974 | ROR1 | Phase II | Head and neck, colorectal, and pancreatic |
| 5 | PRI-724 | Β-catenin/CBP | Phase II | Solid tumors |
| 6 | ETC-59 | PORCN | Phase I | Solid tumors |
| 7 | CGX-1321 | PORCN | Phase I | Solid tumors |
| 8 | Crizotinib | TKI, HGFR | Phase I | GBM |
| 9 | Imatinib | BCR-ABL, c-KIT | Phase II | GBM |
| 10 | Acalabrutinib (ACP-196) | TKI | Phase II | GBM |